Retinal imaging may provide early detection of Alzheimer's disease

Dr. Maya Koronyo-Hamaoui (c) Cedas-Sinai

Preliminary results indicate that a device that has been conceived at Cedars-Sinai and developed by NeuroVision Imaging, may provide highly predictive early detection of changes associated with Alzheimer's disease 15 to 20 years before clinical diagnosis.






This noninvasive optical imaging device can provide early detection of changes that later occur in the brain and are a classic sign of Alzheimer's disease, according to preliminary results from investigators conducting a clinical trial in Australia.

from Cedars-Sinai website

In preliminary results in 40 patients, the test could differentiate between Alzheimer's disease and non-Alzheimer's disease with 100 percent sensitivity and 80.6 percent specificity, meaning that all people with the disease tested positive and most of the people without the disease tested negative. The optical imaging exam appears to detect changes that occur 15-20 years before clinical diagnosis.

The researchers feel that this simple test could allow testing of new therapies at an earlier stage, increasing the chances of altering the course of Alzheimer's disease.

Keith Black, MD, Professor and Chair of Cedars-Sinai's Department of Neurosurgery, Director of the Maxine Dunitz Neurosurgical Institute and the Ruth and Lawrence Harvey Chair in Neuroscience, said the accumulation of beta-amyloid plaque in the brain is a hallmark sign of Alzheimer's, but current tests detect changes only after the disease has advanced to late stages. Researchers believe that as treatment options improve, early detection will be critical, but existing diagnostic methods are inconvenient, costly and impractical for routine screening. PET scans require the use of radioactive tracers, and cerebrospinal fluid analysis requires that patients undergo invasive and often painful lumbar punctures, but neither approach is quite feasible, especially for patients in the earlier stages of disease.

Positron emission tomography, or PET, is the current diagnostic standard. The retina, unlike other structures of the eye, is part of the central nervous system, sharing many characteristics of the brain. A few years ago, researchers at Cedars-Sinai discovered that the plaques associated with Alzheimer's disease occur not only in the brain but also in the retina. By ‘staining' the plaque with curcumin, a component of the common spice turmeric, these plaques could be detected in the retina even before it began to accumulate in the brain. The device that was developed enables the scientists to look through the eye – just as an ophthalmologist looks through the eye to diagnose retinal disease – and see these changes.

This clinical trial was designed to enable researchers to correlate retinal plaque detected by optical imaging with brain plaque detected by PET scans. Studies involved patients diagnosed with Alzheimer's, a group with mild cognitive impairment and a group of people with no evidence of brain abnormality. The retinal beta-amyloid plaque findings and optical imaging technology began at Cedars-Sinai with studies in live rodents and the post-mortem investigation of human retinas of people who had died with Alzheimer's. Maya Koronyo-Hamaoui, PhD, assistant professor of neurosurgery in the Department of Neurosurgery and the Department of Biomedical Sciences, and Yosef Koronyo, a research scientist, were first authors of the original results that were published in a journal and presented at the AAIC in 2010.

The Australian study is one of several in progress to determine if similar results can be confirmed in humans living with the disease. This large double-blind clinical trial appears to validate the novel human retinal amyloid imaging approach using curcumin labeling, as per the scientists. It further demonstrates significant correlation with brain amyloid burden, thereby predicting accumulation of plaques in the brain through the retina.

The optical imaging technology has been licensed by Cedars-Sinai to NeuroVision Imaging LLC for further development.

The retinal imaging study is being conducted as part of the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing, often referred to as AIBL, a longitudinal research cohort with more than 1,300 subjects. It is a collaborative effort of Austin Health, the CSIRO, Edith Cowan University, the Florey Institute of Neuroscience and Mental Health and the National Ageing Research Institute, with NeuroVision Imaging LLC providing image processing, and data collection and analysis support for the retinal imaging substudy.
 Source